Vertical Deals in Healthcare: Key Antitrust Takeaways

  • As the healthcare sector continues to grapple with the COVID-19 pandemic, it will face increased antitrust scrutiny from the Biden administration, with the Federal Trade Commission (the “FTC”) and Department of Justice, Antitrust Division (the “DOJ”) ramping up their reviews not just of “horizontal” transactions (i.e., deals between competitors), but also of “vertical” transactions (i.e., deals that combine market participants at different levels of the healthcare industry, such as payors, hospitals, and physician practices).

  • Healthcare systems, provider organizations, payers, and private equity firms investing and operating in the healthcare space will encounter increased antitrust scrutiny of transactions combining payors, physicians, facilities, healthcare tech platforms, and other healthcare companies. 

Practice Areas

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.